Abstract
A total of 249 client-owned dogs with osteoarthritis were treated with firocoxib (5 mg/kg/day) or a positive control, etodolac (10-15 mg/kg/day), for 30 days. Veterinary examinations were performed on approximately days 0 (visit 1), 14 (visit 2), and 29 (visit 3). Based on defined noninferiority criteria, firocoxib and etodolac were comparable. Based on the magnitude of the change from baseline, improvement with firocoxib was significantly greater than with etodolac for lameness at a trot (visits 2 and 3) and for lameness at a walk, pain on manipulation, and range of motion (visit 3) (P < .05). In weekly owner evaluations, firocoxib provided significantly greater improvement than etodolac (P < .05) at each scoring.
Publication types
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
4-Butyrolactone / adverse effects
-
4-Butyrolactone / analogs & derivatives*
-
4-Butyrolactone / therapeutic use
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Dog Diseases / drug therapy*
-
Dog Diseases / pathology
-
Dogs
-
Etodolac / adverse effects
-
Etodolac / therapeutic use
-
Female
-
Lameness, Animal / drug therapy
-
Male
-
Osteoarthritis / drug therapy
-
Osteoarthritis / pathology
-
Osteoarthritis / veterinary*
-
Range of Motion, Articular / drug effects
-
Range of Motion, Articular / physiology
-
Safety
-
Sulfones / adverse effects
-
Sulfones / therapeutic use*
-
Treatment Outcome
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Sulfones
-
Etodolac
-
4-Butyrolactone
-
firocoxib